Business
Nxera Pharma to Present at the 44th Annual J.P. Morgan Healthcare Conference
Tokyo, Japan and Cambridge, UK, 5 January 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces that Chris Cargill, President and CEO, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, 13 January 2026 at 1:30 p.m. PST. Investors, analysts, members of the media and the general public are invited to listen to a live audio webcast of the presentation at this weblink. Presentation slides will be made available through the investor section of the Com
About this update from Nxera Pharma Co., Ltd.
[{"type":"image","alt":"Nxera Pharma","displaySize":"","headline":null,"caption":"Nxera Pharma","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":101,"url":"https://media.zenfs.com/en/globenewswire.com/3c5c5d1f11d2ca9444665ce7b9191638"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/MMtO8FGLy1ULu25TBGkF3w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0MTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/3c5c5d1f11d2ca9444665ce7b9191638","width":300,"height":101}},"lazy":false},{"type":"text","content":"Tokyo, Japan and Cambridge, UK, 5 January 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces that Chris Cargill, President and CEO, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, 13 January 2026 at 1:30 p.m. PST.","length":274,"tagName":"p"},{"type":"text","content":"Investors, analysts, members of the media and the general public are invited to listen to a live audio webcast of the presentation at this weblink.","length":147,"tagName":"p"},{"type":"text","content":"Presentation slides will be made available through the investor section of the Company’s website.","length":97,"tagName":"p"},{"type":"text","content":"–END–","length":5,"tagName":"p"},{"type":"text","content":"About Nxera PharmaNxera Pharma is a technology powered biopharma company in pursuit of new specialty medicines to improve the lives of patients with unmet needs in Japan and globally.","length":184,"tagName":"p"},{"type":"text","content":"We have built an agile, new-generation commercial business in Japan to develop and commercialize innovative medicines, including several launched products, to address this high value, large and growing market and those in the broader APAC region.","length":246,"tagName":"p"},{"type":"text","content":"Behind that, and powered by our unique NxWave™ discovery platform, we are advancing an extensive pipeline of over 30 active programs from discovery through to late clinical stage internally and in partnership with leading pharma and biotech companies. This pipeline of potentially first- and best-in-class candidates is focused on addressing major unmet needs in some of the fastest-growing areas of medicine across obesity and metabolic disorders, neurology/neuropsychiatry and immunology and inflammation.","length":507,"tagName":"p"},{"type":"text","content":"Nxera ...